{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:22:09Z","timestamp":1773364929937,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ogc.2022.03.001","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T18:31:39Z","timestamp":1653676299000},"page":"299-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Emerging Treatment Options for Fibroids"],"prefix":"10.1016","volume":"49","author":[{"given":"Briana L.","family":"Baxter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Chun","family":"Hur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S.","family":"Guido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ogc.2022.03.001_bib1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ogc.2022.03.001_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2010.11.011","article-title":"FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age","volume":"113","author":"Munro","year":"2011","journal-title":"Int J Gynecol Obstet"},{"issue":"2","key":"10.1016\/j.ogc.2022.03.001_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ijgo.12266","article-title":"Clinical limitations of the International Federation of Gynecology and Obstetrics (FIGO) classification of uterine fibroids","volume":"139","author":"Laughlin-Tommaso","year":"2017","journal-title":"Int J Gynecol Obstet"},{"issue":"5","key":"10.1016\/j.ogc.2022.03.001_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jpsychores.2014.12.016","article-title":"Beyond the physical: a qualitative assessment of the burden of symptomatic uterine fibroids on women's emotional and psychosocial health","volume":"78","author":"Ghant","year":"2015","journal-title":"J\u00a0Psychosom Res"},{"issue":"3","key":"10.1016\/j.ogc.2022.03.001_bib5","doi-asserted-by":"crossref","first-page":"211.e1-9","DOI":"10.1016\/j.ajog.2011.12.002","article-title":"The estimated annual cost of uterine leiomyomata in the United States","volume":"206","author":"Cardozo","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ogc.2022.03.001_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ijgo.13102","article-title":"Epidemiology and management of uterine fibroids","volume":"149","author":"Giuliani","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"10.1016\/j.ogc.2022.03.001_bib7","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/AOG.0000000000002785","article-title":"Moving Toward Individualized Medicine for Uterine Leiomyomas","volume":"132","author":"Laughlin-Tommaso","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.ogc.2022.03.001_bib8","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.22239","article-title":"Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978\u20132001: An analysis of 26,758 cases","volume":"119","author":"Toro","year":"2006","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ogc.2022.03.001_bib9","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/AOG.0000000000004291","article-title":"Uterine Morcellation for Presumed Leiomyomas: ACOG Committee Opinion, Number 822","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2022.03.001_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jmig.2017.08.642","article-title":"Non-surgical Management of Myomas","volume":"25","author":"Laughlin-Tommaso","year":"2018","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"6","key":"10.1016\/j.ogc.2022.03.001_bib11","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/AOG.0000000000004401","article-title":"Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.ogc.2022.03.001_bib12","first-page":"Cd000400","article-title":"Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding","volume":"9","author":"Bofill Rodriguez","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ogc.2022.03.001_bib13","first-page":"Cd000249","article-title":"Antifibrinolytics for heavy menstrual bleeding","volume":"4","author":"Bryant-Smith","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ogc.2022.03.001_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bpobgyn.2017.09.007","article-title":"Medical therapy for fibroids: An overview","volume":"46","author":"Sinai Talaulikar","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.ogc.2022.03.001_bib15","first-page":"Cd000154","article-title":"Combined hormonal contraceptives for heavy menstrual bleeding","volume":"2","author":"Lethaby","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ogc.2022.03.001_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6503a1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.ogc.2022.03.001_bib17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/AOG.0b013e3182839e0e","article-title":"Nonsurgical management of heavy menstrual bleeding: a systematic review","volume":"121","author":"Matteson","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ogc.2022.03.001_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.fertnstert.2020.07.028","article-title":"Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist","volume":"114","author":"Donnez","year":"2020","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.ogc.2022.03.001_bib19","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/AOG.0000000000002933","article-title":"Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial","volume":"132","author":"Carr","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.ogc.2022.03.001_bib20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ogc.2022.03.001_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ajog.2017.12.206","article-title":"The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids","volume":"218","author":"Singh","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ogc.2022.03.001_bib22","first-page":"CD010770","article-title":"Selective progesterone receptor modulators (SPRMs) for uterine fibroids","volume":"2017","author":"Murji","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ogc.2022.03.001_bib23","series-title":"Management of uterine fibroids","article-title":"AHRQ Comparative Effectiveness Reviews","author":"Hartmann","year":"2017"},{"issue":"6","key":"10.1016\/j.ogc.2022.03.001_bib24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"issue":"3","key":"10.1016\/j.ogc.2022.03.001_bib25","first-page":"305","article-title":"SOGC clinical practice guidelines. Uterine fibroid embolization (UFE). Number 150, October 2004","volume":"89","year":"2005","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.ogc.2022.03.001_bib26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1148\/radiol.2016141693","article-title":"Management of Uterine Fibroids: A Focus on Uterine-sparing Interventional Techniques","volume":"280","author":"Silberzweig","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.ogc.2022.03.001_bib27","first-page":"Cd005073","article-title":"Uterine artery embolization for symptomatic uterine fibroids","volume":"12","author":"Gupta","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.ogc.2022.03.001_bib28","doi-asserted-by":"crossref","first-page":"745.e1-2","DOI":"10.1016\/j.ajog.2016.06.051","article-title":"Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial","volume":"215","author":"De Bruijn","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ogc.2022.03.001_bib29","doi-asserted-by":"crossref","first-page":"109801","DOI":"10.1016\/j.ejrad.2021.109801","article-title":"Systematic review of reproductive outcomes after High Intensity Focused Ultrasound treatment of uterine fibroids","volume":"141","author":"Anneveldt","year":"2021","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.ogc.2022.03.001_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00270-012-0367-3","article-title":"MR-Guided Focused Ultrasound for the Treatment of Uterine Fibroids","volume":"36","author":"Hesley","year":"2013","journal-title":"CardioVascular Interv Radiol"},{"issue":"5","key":"10.1016\/j.ogc.2022.03.001_bib31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00330-014-3538-6","article-title":"MRI predictors of clinical success in MR-guided focused ultrasound (MRgFUS) treatments of uterine fibroids: results from a single centre","volume":"25","author":"Mindjuk","year":"2015","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.ogc.2022.03.001_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5152\/dir.2018.18111","article-title":"Review of influential clinical factors in reducing the risk of unsuccessful MRI-guided HIFU treatment outcome of uterine fibroids","volume":"24","author":"Duc","year":"2018","journal-title":"Diagn Interv Radiol"},{"issue":"4","key":"10.1016\/j.ogc.2022.03.001_bib33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s13669-016-0183-x","article-title":"Radiofrequency Ablation of Uterine Fibroids: a Review","volume":"5","author":"Lee","year":"2016","journal-title":"Curr Obstet Gynecol Rep"},{"issue":"12","key":"10.1016\/j.ogc.2022.03.001_bib34","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1089\/lap.2019.0550","article-title":"Clinical Performance of Radiofrequency Ablation for Treatment of Uterine Fibroids: Systematic Review and Meta-Analysis of Prospective Studies","volume":"29","author":"Bradley","year":"2019","journal-title":"J\u00a0Laparoendoscopic Adv Surg Tech"},{"issue":"1","key":"10.1016\/j.ogc.2022.03.001_bib35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/02656736.2018.1564843","article-title":"Nonresective treatments for uterine fibroids: a systematic review of uterine and fibroid volume reductions","volume":"36","author":"Taheri","year":"2019","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"10.1016\/j.ogc.2022.03.001_bib36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jmig.2011.02.006","article-title":"Laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation of symptomatic uterine leiomyomas: feasibility study using the Halt 2000 Ablation System","volume":"18","author":"Garza Leal","year":"2011","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"5","key":"10.1016\/j.ogc.2022.03.001_bib37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jmig.2014.02.015","article-title":"Three-year outcome of the Halt trial: a prospective analysis of radiofrequency volumetric thermal ablation of myomas","volume":"21","author":"Berman","year":"2014","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"05","key":"10.1016\/j.ogc.2022.03.001_bib38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-0035-1545931","article-title":"Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial","volume":"75","author":"Hahn","year":"2015","journal-title":"Geburtshilfe und Frauenheilkunde"},{"key":"10.1016\/j.ogc.2022.03.001_bib39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/CEOR.S155038","article-title":"Clinical outcomes and health care utilization pre- and post-laparoscopic radiofrequency ablation of symptomatic fibroids and laparoscopic myomectomy: a randomized trial of uterine-sparing techniques (TRUST) in Canada","volume":"10","author":"Rattray","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ogc.2022.03.001_bib40","first-page":"CD003677","article-title":"Surgical approach to hysterectomy for benign gynaecological disease","volume":"8","author":"Aarts","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ogc.2022.03.001_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10397-015-0915-3","article-title":"The FAST-EU trial: 12-month clinical outcomes of women after intrauterine sonography-guided transcervical radiofrequency ablation of uterine fibroids","volume":"13","author":"Br\u00f6lmann","year":"2016","journal-title":"Gynecol Surg"},{"key":"10.1016\/j.ogc.2022.03.001_bib42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CEOR.S253891","article-title":"The CHOICES Study: Facility Level Comparative Cost, Resource Utilization, and Outcomes Analysis of Myomectomy Compared to Transcervical Fibroid Ablation","volume":"12","author":"Brooks","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.ogc.2022.03.001_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/AOG.0000000000003032","article-title":"Ultrasound-Guided Transcervical Ablation of Uterine Leiomyomas","volume":"133","author":"Chudnoff","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ogc.2022.03.001_bib44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/gyn.2020.0021","article-title":"Three-Year Results of the SONATA Pivotal Trial of Transcervical Fibroid Ablation for Symptomatic Uterine Myomata","volume":"36","author":"Lukes","year":"2020","journal-title":"J\u00a0Gynecol Surg"},{"issue":"1","key":"10.1016\/j.ogc.2022.03.001_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/gyn.2018.0051","article-title":"Long-Term Clinical Outcomes of Transcervical Radiofrequency Ablation of Uterine Fibroids: The VITALITY Study","volume":"35","author":"Garza-Leal","year":"2019","journal-title":"J\u00a0Gynecol Surg"},{"issue":"6","key":"10.1016\/j.ogc.2022.03.001_bib46","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/gyn.2019.0012","article-title":"Transcervical Radiofrequency Ablation of Symptomatic Uterine Fibroids: 2-Year Results of the SONATA Pivotal Trial","volume":"35","author":"Miller","year":"2019","journal-title":"J\u00a0Gynecol Surg"},{"issue":"1","key":"10.1016\/j.ogc.2022.03.001_bib47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijgo.13638","article-title":"Transcervical fibroid ablation with the Sonata\u2122 system for treatment of submucous and large uterine fibroids","volume":"155","author":"Shifrin","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"10.1016\/j.ogc.2022.03.001_bib48","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jmig.2010.04.015","article-title":"Risk factors for uterine rupture after laparoscopic myomectomy","volume":"17","author":"Parker","year":"2010","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"4","key":"10.1016\/j.ogc.2022.03.001_bib49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jmig.2007.01.013","article-title":"Italian multicenter study on complications of laparoscopic myomectomy","volume":"14","author":"Sizzi","year":"2007","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"5","key":"10.1016\/j.ogc.2022.03.001_bib50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/gyn.2019.0033","article-title":"The INTEGRITY Trial: Preservation of Uterine-Wall Integrity 12 Months After Transcervical Fibroid Ablation with the Sonata System","volume":"35","author":"Bongers","year":"2019","journal-title":"J\u00a0Gynecol Surg"},{"key":"10.1016\/j.ogc.2022.03.001_bib51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejogrb.2019.09.013","article-title":"Evaluation of uterine patency following transcervical uterine fibroid ablation with the Sonata system (the OPEN clinical trial)","volume":"242","author":"Bongers","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"10.1016\/j.ogc.2022.03.001_bib52","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jmig.2017.01.009","article-title":"Pregnancy Outcomes After Direct Uterine Myoma Thermal Ablation: Review of the Literature","volume":"24","author":"Keltz","year":"2017","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"3","key":"10.1016\/j.ogc.2022.03.001_bib53","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rbmo.2020.01.003","article-title":"Systematic review of pregnancy outcomes after fertility-preserving treatment of uterine fibroids","volume":"40","author":"Khaw","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ogc.2022.03.001_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmig.2022.01.015","article-title":"Radiofrequency ablation of uterine fibroids and pregnancy outcomes: an updated review of the literature","author":"Polin","year":"2022","journal-title":"J\u00a0Minimally Invasive Gynecol"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854522000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854522000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:25:29Z","timestamp":1760178329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854522000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0889854522000353"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2022.03.001","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Treatment Options for Fibroids","name":"articletitle","label":"Article Title"},{"value":"Obstetrics and Gynecology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogc.2022.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}